Literature DB >> 1133157

In vitro determination of relative corticosteroid potency.

H L Cantrill, S R Waltman, P F Palmberg, H A Zink, B Becker.   

Abstract

The corticosteroid concentration required to inhibit phytohemagglutinin stimulated human lymphocyte transformation by 50% was determined for three corticosteroids. The relative potency of hydrocortisone, prednisolone and dexamethasone determined in 16 patients was 1.00, 2.43, and 24.7 respectively. This assay is proposed as an objective tool for comparison of relative corticosteroid potency in man.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1133157     DOI： 10.1210/jcem-40-6-1073

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


  9 in total

1.  Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology Group.

Authors:  Susan J Lindemulder; Linda C Stork; Bruce Bostrom; Xiaomin Lu; Meenakshi Devidas; Stephen Hunger; Joseph P Neglia; Nina S Kadan-Lottick
Journal:  Pediatr Blood Cancer       Date:  2015-02-07       Impact factor: 3.167

2.  Efficacy and toxicity of dexamethasone vs methylprednisolone-long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002.

Authors:  A Karachunskiy; J Roumiantseva; S Lagoiko; C Bührer; G Tallen; O Aleinikova; O Bydanov; N Korepanova; L Bajdun; T Nasedkina; A von Stackelberg; G Novichkova; A Maschan; D Litvinov; N Myakova; N Ponomareva; K Kondratchik; L Fechina; O Streneva; N Judina; G Scharapova; A Shamardina; I Gerbek; A Shapochnik; A Rumjanzew; G Henze
Journal:  Leukemia       Date:  2015-03-09       Impact factor: 11.528

3.  Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia.

Authors:  Nicholas S Phillips; Yin Ting Cheung; John O Glass; Matthew A Scoggins; Wei Liu; Robert J Ogg; Daniel A Mulrooney; Ching-Hon Pui; Leslie L Robison; Wilburn E Reddick; Melissa M Hudson; Kevin R Krull
Journal:  Pediatr Blood Cancer       Date:  2019-08-12       Impact factor: 3.167

4.  Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Authors:  Boris Labar; Stefan Suciu; Roel Willemze; Petra Muus; Jean-Pierre Marie; Georges Fillet; Zwi Berneman; Branimir Jaksic; Walter Feremans; Dominique Bron; Harm Sinnige; Martin Mistrik; Gerard Vreugdenhil; Robrecht De Bock; Damir Nemet; Caroline Gilotay; Sergio Amadori; Theo de Witte
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 5.  Glucocorticoid use in acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2010-10-12       Impact factor: 41.316

6.  Influence of glucocorticoids on histamine release and 45calcium uptake by isolated rat mast cells.

Authors:  N Grosman; S M Jensen
Journal:  Agents Actions       Date:  1984-01

7.  Inhibition of proliferation, migration and proteolysis contribute to corticosterone-mediated inhibition of angiogenesis.

Authors:  Eric A Shikatani; Anastassia Trifonova; Erin R Mandel; Sammy T K Liu; Emilie Roudier; Anna Krylova; Andrei Szigiato; Jacqueline Beaudry; Michael C Riddell; Tara L Haas
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

8.  The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy.

Authors:  Viktória Szabó; Gábor Borgulya; Tamás Filkorn; Judit Majnik; Ilona Bányász; Zoltán Zsolt Nagy
Journal:  Mol Vis       Date:  2007-04-27       Impact factor: 2.367

9.  The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells.

Authors:  Daniel Bindreither; Simone Ecker; Barbara Gschirr; Anita Kofler; Reinhard Kofler; Johannes Rainer
Journal:  BMC Genomics       Date:  2014-08-07       Impact factor: 3.969
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.